Table 1. Characteristics of studies included in the meta-analysis.

Study	Subjects group	N	Group	Follow up (m)	Definition of remission	Quality score
Shi SF 2011 [16]	IgAN	294	IS+RASB, RASB	12	Remission: proteinuria < 1.0 g/d	7
Morigama T 2012 [13]	Nephrotic IgAN	42	Steroid, Non-steroid	48	Incomplete remission: proteinuria < 1.0 g/d	8
Kang ZJ 2015 [14]	IgAN children with NS	58	Steroid, MMF	17	Remission: proteinuria < 0.3 g/gIncomplete remission: < 50% reduction in proteinuria	7
Tesar V 2015 [17]	Children and adults with IgAN	184	Steroid + RASB, RASB	52	Remission: proteinuria < 1.0 g/dResistance: proteinuria > 1.0 g/d	9
Katafuchi R 2016 [15]	IgAN with proteinuria 1.0 - 3.5 g/d	59	Tonsillectom + steroid, Steroid	12	Remission: proteinuria < 0.3 g/g or proteinuria < 0.3 g/d	8

N, number; IgAN, immunoglobulin A nephropathy; IS, immunosuppression; RASB, rennin angiotensin system blockade; NS, nephritic syndrome; MMF, mycophenolate mofetil